Phase 3
Completed N=13,885
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
Source: ClinicalTrials.gov NCT01732822 ↗Enrolled (actual)
13,885
Serious AEs
25.3%
Results posted
Oct 2017
Primary outcomePrimary: Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke — 751; 740 Participants — p=0.650
◆ Published Evidence
Emerging
16citations · ~4 / year
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial.
Summary
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
Linked Publications (5)
-
Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial.
-
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.
-
World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial.
-
Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial.
-
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y<sub>12</sub> inhibitors: Insights from the EUCLID trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke |
751; 740 | 0.650 |
| SECONDARY Composite of CV Death, MI, Ischemic Stroke, and ALI |
839; 833 | 0.738 |
| SECONDARY CV Death |
363; 343 | 0.400 |
| SECONDARY MI |
349; 334 | 0.482 |
| SECONDARY All-cause Mortality |
628; 635 | 0.913 |
| SECONDARY Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic) |
766; 759 | 0.724 |
| SECONDARY ALI |
117; 115 | 0.846 |
| SECONDARY Lower Extremity Revascularization |
846; 892 | 0.298 |
| SECONDARY Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other]) |
1211; 1250 | 0.462 |
Eligibility Criteria
Inclusion Criteria
- Male and Female patients 50 years old or older Symptomatic peripheral artery disease
Exclusion Criteria
- Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation
- Patients with known bleeding disorders
- Patients with a history of intracranial bleed
- Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker
Data sourced from ClinicalTrials.gov (NCT01732822) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.